BRIEF-Janssen to develop and commercialize JAK inhibitor

Oct 1 (Reuters) -

* Janssen announces worldwide agreement to develop and commercialize JAK

inhibitor for immunological diseases

* Janssen -Janssen gains exclusive worldwide rights to develop and

commercialize ASP015K, except in Japan

* Janssen -entered into a license agreement with Astellas Pharma for worldwide

development and commercialization of ASP015K

* Janssen -Astellas will continue development and commercialization of ASP015K

in Japan

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))